CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
- Resource Type
- Academic Journal
- Authors
- Walls GM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK.; Oughton JB; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Chalmers AJ; Institute of Cancer Sciences, University of Glasgow, Scotland, UK.; Brown S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Collinson F; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Forster MD; Department of Oncology, UCL Cancer Institute, England, UK.; Franks KN; St James' Institute of Oncology, University of Leeds, England, UK.; Gilbert A; St James' Institute of Oncology, University of Leeds, England, UK.; Hanna GG; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.; Hannaway N; Newcastle University, Newcastle upon Tyne, England, UK.; Harrow S; The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK.; Haswell T; Patient and Public Involvement Advocacy, UK.; Hiley CT; Department of Oncology, UCL Cancer Institute, England, UK.; Hinsley S; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Institute of Cancer Sciences, University of Glasgow, Scotland, UK.; Krebs M; Faculty of Biology, Medicine and Health, University of Manchester, England, UK.; Murden G; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Phillip R; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Ryan AJ; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK.; Salem A; The Christie NHS Foundation Trust/University of Manchester, Manchester, England, UK.; Sebag-Montefoire D; St James' Institute of Oncology, University of Leeds, England, UK.; Shaw P; Velindre University NHS Trust, Cardiff, Wales, UK.; Twelves CJ; St James' Institute of Oncology, University of Leeds, England, UK.; Walker K; Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.; Young RJ; Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, England, UK.; Faivre-Finn C; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England, UK.; Greystoke A; Newcastle University, Newcastle upon Tyne, England, UK.
- Source
- Publisher: Elsevier Ireland Ltd. on behalf of European Society for Radiotherapy and Oncology Country of Publication: Ireland NLM ID: 101713416 Publication Model: eCollection Cited Medium: Internet ISSN: 2405-6308 (Electronic) Linking ISSN: 24056308 NLM ISO Abbreviation: Clin Transl Radiat Oncol Subsets: PubMed not MEDLINE
- Subject
- Language
- English
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.)